Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Mr. James E. DavisChairman, CEO & President | -10,00k | 1,94M | Automatic Disposition | 194,14 | 132,42k | -7,02% |
| 2026-03-05 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -3,88k | 799,68k | Automatic Disposition | 206,21 | 43,29k | -8,22% |
| 2026-03-04 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -3,35k | 687,10k | Sale to Issuer | 204,86 | 43,29k | -7,19% |
| 2026-03-04 | Mr. Mark E. DelaneySenior VP & Chief Commercial Officer | -2,33k | 476,50k | Sale to Issuer | 204,86 | 11,86k | -16,39% |
| 2026-03-05 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -5,56k | 1,15M | Automatic Disposition | 206,21 | 71,62k | -7,20% |
| 2026-03-04 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -5,81k | 1,19M | Sale to Issuer | 204,86 | 71,62k | -7,50% |
| 2026-03-04 | Mr. Sam A. SamadExec. VP & CFO | -7,72k | 1,58M | Sale to Issuer | 204,86 | 33,27k | -18,83% |
| 2026-03-05 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -2,86k | 588,73k | Automatic Disposition | 206,21 | 15,20k | -15,81% |
| 2026-03-04 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -2,83k | 579,14k | Sale to Issuer | 204,86 | 15,20k | -15,68% |
| 2026-03-04 | Mr. James E. DavisChairman, CEO & President | -26,41k | 5,41M | Sale to Issuer | 204,86 | 142,42k | -15,64% |
| 2026-03-04 | Mr. Michael J. DeppeSenior VP, Corporate Controller & CAO | -750,00 | 153,65k | Sale to Issuer | 204,86 | 35,90k | -2,05% |
| 2026-03-04 | Mr. Karthik KuppusamySVP of Clinical Solutions | -2,63k | 538,37k | Verkauf | 204,86 | 15,46k | -14,53% |
| 2026-03-03 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -526,00 | 109,27k | Automatic Disposition | 207,73 | 43,29k | -1,20% |
| 2026-03-02 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -288,00 | 59,00k | Sale to Issuer | 204,86 | 43,29k | -0,66% |
| 2026-03-03 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -632,00 | 131,29k | Automatic Disposition | 207,73 | 71,62k | -0,87% |
| 2026-03-02 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -648,00 | 132,75k | Sale to Issuer | 204,86 | 71,62k | -0,90% |
| 2026-03-02 | Mr. Sam A. SamadExec. VP & CFO | -869,00 | 178,02k | Sale to Issuer | 204,86 | 27,04k | -3,11% |
| 2026-03-03 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -410,00 | 85,17k | Automatic Disposition | 207,73 | 15,20k | -2,63% |
| 2026-03-02 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -230,00 | 47,12k | Sale to Issuer | 204,86 | 15,20k | -1,49% |
| 2026-03-02 | Mr. James E. DavisChairman, CEO & President | -10,00k | 2,13M | Automatic Disposition | 212,52 | 117,19k | -7,86% |
| 2026-03-02 | Mr. James E. DavisChairman, CEO & President | -2,97k | 608,02k | Sale to Issuer | 204,86 | 117,19k | -2,47% |
| 2026-03-02 | Mr. Mark E. DelaneySenior VP & Chief Commercial Officer | -188,00 | 38,51k | Sale to Issuer | 204,86 | 8,51k | -2,16% |
| 2026-03-02 | Mr. Karthik KuppusamySVP of Clinical Solutions | -205,00 | 42,00k | Sale to Issuer | 204,86 | 11,89k | -1,70% |
| 2026-03-02 | Mr. Michael J. DeppeSenior VP, Corporate Controller & CAO | -88,00 | 18,03k | Sale to Issuer | 204,86 | 35,18k | -0,25% |
| 2026-02-18 | Mr. Sam A. SamadExec. VP & CFO | -1,87k | 388,62k | Sale to Issuer | 206,99 - 210,01 | 27,84k | -6,28% |
| 2026-02-19 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -958,00 | 196,23k | Automatic Disposition | 204,83 | 15,84k | -5,70% |
| 2026-02-18 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -537,00 | 111,89k | Sale to Issuer | 206,99 - 210,01 | 15,84k | -3,28% |
| 2026-02-18 | Mr. James E. DavisChairman, CEO & President | -6,18k | 1,29M | Sale to Issuer | 206,99 - 210,01 | 130,15k | -4,54% |
| 2026-02-19 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -1,11k | 227,57k | Automatic Disposition | 204,83 | 44,11k | -2,46% |
| 2026-02-18 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -648,00 | 135,04k | Sale to Issuer | 206,99 - 210,01 | 44,11k | -1,45% |
| 2026-02-18 | Mr. Karthik KuppusamySVP of Clinical Solutions | -511,00 | 106,53k | Sale to Issuer | 206,99 - 210,01 | 12,06k | -4,06% |
| 2026-02-19 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -1,43k | 293,52k | Automatic Disposition | 204,83 | 72,91k | -1,93% |
| 2026-02-18 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -1,16k | 241,62k | Sale to Issuer | 206,99 - 210,01 | 72,91k | -1,57% |
| 2026-02-18 | Mr. Mark E. DelaneySenior VP & Chief Commercial Officer | -435,00 | 90,66k | Sale to Issuer | 206,99 - 210,01 | 8,68k | -4,77% |
| 2026-02-18 | Mr. Michael J. DeppeSenior VP, Corporate Controller & CAO | -182,00 | 37,92k | Sale to Issuer | 206,99 - 210,01 | 35,27k | -0,51% |
| 2026-02-13 | Ms. Catherine T. DohertyExec. VP of Regional Businesses | -26,17k | 2,46M | Derivative Exercise and Sale | 112,17 - 209,10 | 72,57k | - |
| 2026-02-10 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -5,66k | 465,39k | Derivative Exercise and Sale | 121,81 - 204,00 | 15,38k | - |
| 2025-11-25 | Mr. James E. DavisChairman, CEO & President | -55,09k | 5,31M | Derivative Exercise and Sale | 95,80 - 192,97 | 120,48k | - |
| 2025-11-25 | Ms. Vicky Brown GreggIndependent Director | -1,25k | 239,70k | Verkauf | 191,76 | 17,04k | -6,84% |
| 2025-11-18 | Mr. Mark E. DelaneySenior VP & Chief Commercial Officer | -7,95k | 340,84k | Derivative Exercise and Sale | 143,33 - 187,35 | 7,53k | - |
| 2025-11-05 | Mr. James E. DavisChairman, CEO & President | -7,14k | 1,25M | Sale to Issuer | 175,57 | 120,48k | -5,60% |
| 2025-10-22 | Mr. Gary M. PfeifferIndependent Director | -1,48k | 270,32k | Verkauf | 182,40 | 29,43k | -4,79% |
| 2025-10-23 | Mr. Gary M. PfeifferIndependent Director | -4,41k | 0,00 | Derivative Disposition Under Employee Benefit Plan | - | 0,00 | -100,00% |
| 2025-09-26 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -227,00 | 19,20k | Derivative Exercise and Sale | 103,57 - 188,66 | 43,81k | - |
| 2025-09-23 | Mr. Michael E. PrevoznikSenior VP & General Counsel | -28,46k | 2,38M | Derivative Exercise and Sale | 103,57 - 187,12 | 43,81k | - |
| 2025-08-21 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -1,98k | 365,38k | Automatic Disposition | 185,00 | 15,27k | -11,45% |
| 2025-08-19 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -4,53k | 321,00k | Derivative Exercise and Sale | 112,17 - 183,00 | 17,24k | - |
| 2025-08-15 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -1,98k | 355,50k | Automatic Disposition | 180,00 | 17,24k | -10,28% |
| 2025-08-13 | Mr. Karthik KuppusamySVP of Clinical Solutions | -123,00 | 21,64k | Sale to Issuer | 175,91 | 10,32k | -1,18% |
| 2025-08-06 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -3,56k | 314,60k | Derivative Exercise and Sale | 86,63 - 175,00 | 19,22k | - |
| 2025-08-06 | Mr. Patrick T. PlewmanSVP of Diagnostic Services | -1,98k | 345,63k | Automatic Disposition | 175,00 | 19,22k | -9,32% |
| 2025-07-30 | Mr. Karthik KuppusamySVP of Clinical Solutions | -8,27k | 534,47k | Derivative Exercise and Sale | 86,63 - 167,40 | 10,44k | - |
| 2025-07-31 | Mr. Karthik KuppusamySVP of Clinical Solutions | -2,21k | 375,70k | Automatic Disposition | 170,00 | 10,44k | -17,47% |
| 2025-07-16 | Mr. Sam A. SamadExec. VP & CFO | -850,00 | 143,66k | Sale to Issuer | 169,01 | 25,60k | -3,21% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
